Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
LQDA

LQDA - Liquidia Corporation Stock Price, Fair Value and News

$36.67-0.91 (-2.42%)
Market Closed

30/100

LQDA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

30/100

LQDA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

LQDA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

LQDA Price Action

Last 7 days

1.8%

Last 30 days

-8.7%

Last 90 days

9.9%

Trailing 12 Months

161.4%

LQDA RSI Chart

LQDA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

LQDA Valuation

Market Cap

3.2B

Price/Earnings (Trailing)

-46.9

Price/Sales (Trailing)

20.41

Price/Free Cashflow

-80.73

LQDA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

LQDA Fundamentals

LQDA Revenue

Revenue (TTM)

158.3M

Rev. Growth (Yr)

3.1K%

Rev. Growth (Qtr)

69.34%

LQDA Earnings

Earnings (TTM)

-68.9M

Earnings Growth (Yr)

137.88%

Earnings Growth (Qtr)

512.95%

LQDA Profitability

Return on Equity

-153.95%

Return on Assets

-21.01%

Free Cashflow Yield

-1.24%

LQDA Investor Care

Shares Dilution (1Y)

3.30%

Diluted EPS (TTM)

-0.8

LQDA Alerts

  • 2 major insider sales recently.
  • Big jump in Revenue (Y/Y)
  • Big jump in Earnings (Y/Y)

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202514.1M19.3M69.2M158.3M
202416.0M14.8M15.6M14.0M
202316.9M17.8M18.3M17.5M
202213.3M13.8M13.8M15.9M
20213.8M6.8M9.8M12.9M
2020000739.6K
20190008.1M
Get all data in R, Python etc through our Historical Stock Data APIs

About Liquidia Corporation

LQDA
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. The company distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
 CEO
 WEBSITEliquidia.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES63

Liquidia Corporation Frequently Asked Questions

LQDA is the stock ticker symbol of Liquidia Corporation. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of Liquidia Corporation is 3.23 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, LQDA's PE ratio (Price to Earnings) is -46.9 and Price to Sales (PS) ratio is 20.41. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LQDA PE ratio will change depending on the future growth rate expectations of investors.